Intelligencia AI: De-risking Drug Development with Explainable AI

Intelligencia AI is a pioneering health tech company that leverages artificial intelligence to transform drug development by providing highly accurate, transparent, and data-driven insights. Designed for pharmaceutical and biotech organizations, its flagship SaaS platform empowers teams across R&D, business development, and licensing to make smarter, faster decisions with confidence. By combining proprietary, expert-curated data—spanning over 1.5 billion clinical and biological data points—with advanced machine learning and explainable AI (using SHAP values), Intelligencia AI delivers precise Probability of Technical and Regulatory Success (PTRS) assessments and phase transition predictions with retrospective accuracy up to 91% and prospective accuracy exceeding 83%. The platform supports real-time analysis, dynamic benchmarking by therapeutic area and indication, and API-driven integration for seamless workflow adoption. Trusted by leading global pharma firms and recognized with a U.S. patent for its innovative forecasting methodology, Intelligencia AI helps organizations reduce failed trials, accelerate investment decisions, and optimize licensing deals—saving millions annually. Its mission is to be a catalyst for change in AI-driven drug development, enabling breakthrough therapies to reach patients faster.

Key Features:

• Portfolio Optimizer™: AI-powered platform for assessing Probability of Technical and Regulatory Success (PTRS) and phase transition probabilities with high accuracy.
• Dynamic Benchmarks: Indication-specific and phase-specific risk assessment tools for strategic planning and competitive analysis.
• Explainable AI (XAI): Transparent insights using SHAP values to identify key drivers behind predictions across hundreds of dimensions.
• Proprietary Ontologies: Advanced data dictionaries that standardize and organize clinical trial data for precise querying and analysis.
• Comprehensive Data Curation: Over 1.5 billion data points from FDA-tracked clinical studies since 1990, curated by biomedical PhDs and updated daily.
• Real-Time Data Updates & API Access: Continuous data synchronization and integration capabilities for external analytics and visualization tools.
• Competitive Landscape Analysis: Enables strategic decision-making for acquisition, licensing, and portfolio management.
• Scenario & Custom Analytics: Tailored insight reports and bespoke analyses for complex business and development planning.
• Objective Risk Evaluation: Standardizes and de-risks go/no-go decisions by reducing subjectivity in clinical development assessments.
• Patented Technology: U.S. Patent No. 11,948,667 for accurate and transparent Probability of Success (PoS) assessments.
• High Validation Standards: Algorithms validated across clinical stages using AUC, Sensitivity/Specificity, Brier Score Loss, and Calibration Curve metrics.
• Cost-Saving Impact: Proven to save $8–25M per year in R&D and $2–5M per month in delayed launch costs.
• Collaborative Support: Dedicated customer success managers and business insights associates for ongoing partnership.

Pricing: Intelligencia AI offers a freemium model with a free inquiry option and paid SaaS subscriptions for Portfolio Optimizer and Dynamic Benchmarks, tailored to enterprise and institutional needs.

Conclusion: Intelligencia AI stands at the forefront of AI innovation in biopharma, delivering unmatched accuracy, transparency, and strategic value to de-risk drug development and accelerate life-changing therapies to market.